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serious cardiac and non-cardiac disease, their in-hospital clinical outcomes were consid-
erably better than those pts treated earlier. Greater selectivity in lesion revascularization
coupled with technical advances such as stents may contribute to these more favorable
results in this important pt population with CAD.
1062-48 Blood Glucose Level Predicts Severity of Renal and 
Myocardial Injury in Diabetic Patients Undergoing 
Coronary Interventions
Bryan J. Robertson, Joseph A. Gascho, Steven M. Ettinger, Ian C. Gilchrist, Mark Kozak, 
Charles E. Chambers, Patrick H. McNulty, Penn State- Milton S. Hershey Medical Center, 
Hershey, PA
Background: Patients with diabetes mellitus (DM) having percutaneous coronary inter-
ventions (PCI) are at increased risk for both contrast nephropathy and adverse cardiac
events. Theoretical considerations suggest glucose itself may mediate these risks by
synergizing with radiocontrast to initiate oxidative injury.
Methods: To test the hypothesis that pre-PCI serum glucose levels predict renal and
myocardial injury, we analyzed 558 DM patients who underwent PCI at our institution
from 1998 to 2002. We stratified 165 patients who had both a 48-hour peak serum creat-
inine (a marker of renal microvascular injury) and a 24-hour peak serum creatine phos-
phokinase (a marker of myocardial microvascular injury) into low glucose (<200 mg/dl,
n=88) and high glucose (>200 mg/dl, n=77) groups. The groups were similar in age (64+/
-14 versus (vs.) 65+/-12 years), gender (43% vs. 46% female), procedure (all balloon +/-
stent), contrast volume received (217+/-100 vs. 239+/-87 ml, p=0.16), and contrast type.
Results: Despite a trend toward better renal function in the high glucose group (creati-
nine=1.2+/-0.9 vs. 1.4+/-1.1 mg/dl, p=0.14), high glucose patients exhibited a greater
post-PCI rise in creatinine (0.26+/-0.5 vs. 0.17+/-0.5 mg/dl, p=0.15), a greater percent
increase in creatinine (21+/-39% vs. 12+/-27%, p=0.03), and a 5-fold higher chance of
suffering a >50% increase in creatinine (10% vs. 2%). High glucose patients were twice
as likely to have a non-Q wave myocardial infarction (40% vs. 21%) with a higher abso-
lute post-PCI CPK than low glucose patients (2666+/-390 vs. 1908+/-368 IU, p=0.07).
Even among patients without a non-Q wave myocardial infarction, high glucose patients
exhibited significantly greater post-PCI peak CPK’s (223+/-220 vs. 153+/-117 IU,
p=0.02).
Conclusion: Almost one-half of DM patients at our institution have blood glucoses >200
mg/dl at the time of PCI. Compared to matched patients with glucose <200 mg/dl, ele-
vated glucose patients exhibit a greater degree of both renal and myocardial injury after
PCI. Because correcting hyperglycemia prior to PCI is easy and inexpensive, the hypoth-
esis that euglycemia might improve outcomes from PCI in DM should be tested in a clini-
cal trial.
1062-49 Clinical Outcome Following Percutaneous Coronary 
Intervention in Patients With End-Stage Renal Disease
Mamoru Toyofuku, Yasuhiko Hayashi, Michinori Imazu, Yoshiko Masaoka, Hironori Ueda, 
Tadamichi Sakuma, Yuji Muraoka, Hidekazu Hirao, Takenori Okada, Shinji Mito, Ken 
Ishibashi, Kentaro Miura, Tsuchiya General Hospital, Hiroshima, Japan
Cardiovascular(CV) mortality remains high in end-stage renal disease(ESRD) with coro-
nary artery disease. Current developments of percutaneous coronary intervention (PCI)
devices may improve immediate and long term outcome in these high risk patients but
data were limited. Methods From the total of 1010 patients (age<80, 1500 lesions) who
underwent PCI between April 2000 to July 2002, we identified 100 patients (179 lesions)
with chronic dialysis. These were followed for one-year and compared with 100 age and
sex matched patients selected from control group. Results: In ESRD, lesions were more
extended (the number of diseased vessels: 1.9 vs. 1.7, p=0.01) and calcification was
more common (52% vs. 10%, p<0.001). The characteristics of procedure in ESRF were
more frequent use of rotablator (43% vs. 8%, p<0.001) and high utilization rate of stent
(74% vs. 73%, NS). In ESRF, the rates of procedural success (97% vs. 98% NS) and
one-year target lesion revascularization(TLR) (26% vs. 21%, NS) were similar in both
groups. However, in hospital death (5% vs. 1% p=0.001), new lesion development which
needed revascularization (27% vs. 10%, p=0.005), and one-year CV mortality rate (15%
vs. 2%, p<0.001) were markedly high in ESRD. In ESRD, factors concerning one-year CV
mortality were elevated CRP, diabetes, and AMI. Multivariate analysis showed elevated
CRP was the strongest predictor of CV mortality (RR2.7 per tertile of CRP, 95%CI 1.3-
5.8). CONCLUSION: The utilization of current PCI devices, such as stent and rotablator,
contributed to high procedural successful rate and acceptable restenosis rate in ESRD.
However, ESRF showed progressive development of new coronary artery lesions and
high mortality rate in short and long term. Elevated CRP was related to the poor progno-
sis.
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1063-51 Clopidogrel Resistance Is Associated With Cytochrome 
3A Polymorphism
Jung W. Suh, Seoul National University Hospital, Seoul, South Korea
Background: Recent reports indicate that there are clopidogrel non-responders in the
population. Clopidogrel is transformed to its active metabolite by cytochrome P450 3A. A
single-nucleotide polymorphism (A6986G) in the CYP3A5 gene distinguishes an expres-
sor (A) and a reduced-expressor (G) allele and largely predicts CYP3A5 content in liver
and intestine. We postulate that clopidogrel resistance is associated with CYP3A5 poly-
morphism and investigated the relationship. Methods & Results: Patients (n=175) treated
clopidogrel after stenting were investigated. We analyzed single nucleotide polymor-
phism (A6986G) by polymerase chain reaction (PCR) and restriction enzyme digestion.
The genotype frequency was GG (97): AG (62): AA (16). The frequency of the GG geno-
type was 0.56, lower than that of Caucasians. But in nine patients who have developed
major adverse cardiac events within 3 months, the frequency of GG genotype was
0.89(GG: AG:AA=8:1:0). In the multivariate analysis including clinical and angiographic
characteristics, the GG genotype was a significant predictor of early MACE(MI, stroke,
SAT, death) after stenting (p=0.044). Follow up angiography was done at 6month
(n=140). The GG genotype was not significant predictor of in-stent restenosis. In order to
confirm the functional significance of the CYP3A5 polymorphism, we administered clopi-
dogrel (300mg loading and 75mg qd for 7days) to nine normal volunteers of AA, AG, GG
genotype (n=3 for each type). We performed platelet aggregation test (baseline, 4hr, 24hr
and 7days). There were tendency that platelet aggregation was more inhibited in the AA
type than non-AA type (AG+GG).Conclusion: CYP 3A5 polymorphism seems to be asso-
ciated with pharmacokinetics of clopidogrel and is associated with the early major
adverse cardiac event after coronary stenting . This polymorphism may explain the indi-
vidual difference in clopidogrel resistance.
1063-52 Lack of Efficacy of Clopidogrel Pretreatment in the 
Prevention of Myocardial Damage After Elective Stent 
Implantation
Dirk J. van der Heijden, Iris C. Westendorp, Robert K. Riezebos, Ferdinand Kiemeneij, 
Ton Slagboom, Ron L. van der Wieken, Gert-Jan Laarman, Onze Lieve Vrouwe 
Gasthuis, Amsterdam, The Netherlands
Background - Non-randomized studies on pre-treatment with ADP receptor blockers of
patients undergoing urgent stent implantation have suggested a reduction in myocardial
damage with pretreatment. In elective stenting the effect of pre-treatment with clopidogrel
has not yet been studied.
Methods - In a randomised trial 3 days pre-treatment with clopidogrel was compared to
standard post-procedural treatment, in addition to aspirin and heparin, in 203 patients
with stable coronary syndromes undergoing elective stentplacement. Primary endpoint
was a rise in troponin I and CK-MB 6 or 24 hours after stentplacement. Secondary end-
points were clinical endpoints at 24 hours, 1 month and 6 months after PCI and a com-
posite endpoint.
Results - No difference was found between not pre-treated and pre-treated patients in
the occurrence of elevation of CK-MB (respectively 6 (6.3%) vs. 7 (7.4%); p=0.78) or
troponin I (respectively 42 (43.3%) vs. 48 (51.1%); p=0.31). Adjustment for baseline val-
ues and possible confounding factors did not change these findings. The composite end-
point occurred in 47 (46.1%) of the not pre-treated patients and in 55 (54.5%) of the pre-
treated patients (p=0.26). Follow up showed no significant difference between the treat-
ment groups in the clinical endpoints.
Conclusion - In this randomized study no beneficial effect of pre-treatment with clopi-
dogrel on the elevation of troponin I, CK-MB or adverse cardiac events after 1 and 6
months could be demonstrated. Therefore we conclude that among patients with stable
coronary syndromes in whom stenting of coronary arteries is planned pre-treatment is
not mandatory in reducing early myocardial damage.
1063-53 A Rational Approach to Coronary Stenting Prior to 
Noncardiac Surgery
Mark Awar, Amit Mittal, Bipin Ravindran, Amit Kalra, Tarang Patel, Nicholas Ruggiero, 
Baback Adibi, Alexander Kaplan, Steven Silver, Paul Walinsky, Howard Weitz, David 
Fischman, Michael Savage, Thomas Jefferson University Hospital, Philadelphia, PA
Background: The optimal timing of noncardiac surgery (NCS) after coronary stenting
has not been determined. Earlier studies showed a high mortality rate due to stent throm-
bosis and perioperative hemorrhage when NCS is performed within two weeks of PCI.
Based on the known temporal course of stent reendothelization we devised the following
four step strategy: 1) A four-week course of clopidogrel post PCI 2) Deferral of elective
NCS for 5 to 12 weeks post stenting 3) Discontinuation of clopidogrel for a minimum of 5
days prior to surgery and 4) Use of heparin coated stents in high-risk patients. The pur-
pose of this study was to validate the clinical efficacy of this therapeutic strategy.
Methods: Forty six patients with significant CAD underwent PCI prior to planned NCS.
NCS was performed at a median of 48 (range: 39-89) days post PCI. All NCS were done
under general anesthesia and consisted of the following: Abdominal 35%, orthopedic
24%, vascular 15%, carotid 13%, thoracic 9% and miscellaneous 4%. In- hospital out-
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comes were assessed for perioperative adverse cardiac events including death, STEMI,
NSTEMI, stent thrombosis, and target vessel revascularization (TVR). NSTEMI was
defined by meeting 2 of the following criteria: Chest pain > 30 minutes, new ECG
changes consistent with ischemia and troponin or CK-MB elevation > 2 times the upper
limit of normal. Major bleeding, defined as postoperative transfusion or need for reopera-
tion, was also assessed.
Results: The study population consisted of 32 men and 14 women with a mean age of
68 years. 37% of patients had diabetes. PCI was successful and uncomplicated in all
patients. A total of 58 lesions were treated with 62 stents, of which 55% were heparin
coated. Clopidogrel was stopped at a median of 6 days prior to surgery. Following NCS,
there were no deaths, STEMI or stent thrombosis. The only perioperative complication
was one NSTEMI (2.2%) which led to TVR of a new lesion. Two patients (4.3%) required
postoperative blood transfusion.
Conclusion: NCS can be safely performed after coronary stenting utilizing a therapeutic
strategy of deferring surgery for greater than 5 weeks, discontinuing clopidogrel before-
hand, and using heparin coated stents in high-risk patients.
1063-54 Long-Term Clopidogrel Therapy Is Particularly 
Beneficial for Patients Requiring Repeat 
Revascularization After an Initial Percutaneous 
Coronary Intervention
Jacqueline Saw, Eric J. Topol, Steven R. Steinhubl, Danielle Brennan, Peter B. Berger, 
David J. Moliterno, Cleveland Clinic Foundation, Cleveland, OH, University of North 
Carolina, Chapel Hill, NC
Background: Long-term clopidogrel improves clinical outcome after PCI. We hypothe-
sized that long-term therapy may be particularly beneficial among patients developing
recurrent stenosis (restenosis).
Methods: CREDO was a randomized, double-blind, placebo-controlled trial comparing
clopidogrel pretreatment (300mg) and 1yr therapy (75mg/d), with no pretreatment and
1mth clopidogrel [control] after PCI. All patients received aspirin. The 1yr primary end-
point was a composite of death, MI, and stroke. We performed a post-hoc analysis evalu-
ating the clinical efficacy of long-term clopidogrel compared with placebo among patients
having 0, 1, or >2 revascularization procedures (ie medical therapy, index PCI only, or
index PCI and subsequent PCI or CABG).
Results: Of 1874 patients enrolled, 2.9%, 76.7%, and 16.4% had 0, 1, and >2 proce-
dures respectively. For the overall study population, the primary endpoint was signifi-
cantly reduced with long-term clopidogrel compared to control (8.5% vs 11.5%, RRR
26.9%, p=0.025). Patients who did not undergo the index PCI (medical therapy or CABG)
had no overt benefit with clopidogrel. Those who underwent only the index PCI had a
trend in primary events reduction with clopidogrel (7.7% vs 9.6%, RRR 21.7%, p=0.19).
In contrast, those requiring repeat revascularization had marked benefit with long-term
clopidogrel (15.4% vs 24.1%, RRR 42.4%, p=0.05).
Conclusions: Long-term clopidogrel after PCI particularly benefits those requiring
repeat revascularization. 
1063-55 A Pharmaco-Epidemiological Study of the Interaction 
Between Atorvastatin and Clopidogrel Following 
Percutaneous Coronary Interventions
James Brophy, Vania Costa, Mohan Babapulle, McGill University Health Center, 
Montreal, PQ, Canada
Background: Clopidogrel is commonly used following PCI to prevent thrombotic compli-
cations. A theoretical concern has been raised that atorvastatin by inhibition of the
CYP3A4 enzyme may competitively inhibit the metabolism of the prodrug clopidogrel
potentially negating these benefits. However, no clinical studies have tested this hypothe-
sis.
Methods: Using the computerized administrative databases from the Province of
Québec, we identified all patients who had PCI between 1998 and 2000, survived until
hospital discharge and received a prescription for clopidogrel within 7 days of a PCI. The
relative risk (RR) of the composite endpoint of death, hospitalizations due to myocardial
infarction or unstable angina, repeat revascularization procedures and stroke during the
next 30 days was compared between patients receiving and not receiving a prescription
for atorvastatin concomitantly. Rates were adjusted by a multivariate logistic regression
model for other medications, disease severity, associated comorbidities and demo-
graphic variables.
Results: There were 3,545 patients included in the analysis, 858 exposed and 2,687 not
exposed to atorvastatin. Adjusted 30 day RR were increased to 2.04 (95% CI 1.29 , 3.23)
in patients prescribed atorvastatin with clopidogrel compared to those not prescribed
atorvastatin. Other CYP3A4 inhibitors (RR 1.85, 95% CI 1.28, 2.69), male gender (RR
1.57, 95% CI 1.04, 2.35), previous MI (RR 1.67, 95% CI 1.16, 2.41), and heart failure
(RR 2.53, 95% CI 1.17 , 5.47) were also associated with increased risks while the use of
aspirin or ticlopidine (RR 0.61, 95% CI 0.41, 0.91) was protective. Limiting the analysis to
only patients receiving both clopidogrel and statins again showed an increased risk with
atorvastatin (RR 1.98, 95% CI 1.22, 3.21).
Conclusion: An association between the concomitant use of atorvastatin and clopidogrel
and adverse cardiovascular events following PCI has been found. The significance of this
putative interaction merits further study.
1063-56 A Randomized Comparison of Cilostazol Versus 
Clopidogrel After Coronay Stenting: The Preliminary 
Results
Seong-Wook Park, Seung-Whan Lee, Young-Hak Kim, Ki Hoon Han, Jung-Sook Auh, 
Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
Background: Although cilostazol, cyclic adenosine monophosphate phosphodiesterase
inhibitor, is used to prevent subacute stent thrombosis, its safety and efficacy have not
been compared with clopidogrel in a randomized manner.
Methods: Patients (n=651) who underwent coronary stenting were randomly assigned to
receive cilostazol (n=325, 477 lesions) or clopidogrel (n=326, 495 lesions) in addition to
200 mg aspirin. Loading dose (cilostazol 200mg or clopidogrel 300mg) was adminis-
trated immediately after coronary steniting. Study drugs were given for one month (cil-
ostazol 100mg bid or clopidogrel 75mg qd). The primary end point consisted of subacute
stent thrombosis or major adverse cardiac events (death, myocardial infarction, repeat
intervention) within 30 days. The secondary end points were peripheral vascular compli-
cation, major bleeding, and any adverse events (neutropenia, thrombocytopenia, skin
rash, liver dysfunction, and gastrointestinal trouble) requiring termination of study drugs
during treatment period.
Results: Study patients included 83 patients (12.7%) with primary stenting for acute
myocardial infarction. Subacute stent thrombosis occurred in 2 patients (0.6%) of cilosta-
zol group and 2 patient (0.6%) of clopidogrel group (p=0.99). Four deaths occurred dur-
ing follow-up in 2 patients (0.6%) of cilostazol group and 2 patient (0.6%) of clopidogrel
group (p=0.99). The primary end point was reached in 1.5% of cilostazol group and 1.5%
of clopidogrel group (p=0.99). The bleeding and vascular complication was seen in 0.6 %
of cilostazol group and 0.3% of clopidogrel group. Serious hematologic complications
were not observed in the two groups. Study drug-related side effects requiring cessation
of study drugs were not statistically different between two groups (0.6 % vs. 0.3 %,
p=0.56).
Conclusions: Preliminary results of this ongoing study show that the regimen with cil-
ostazol and aspirin appears to be safe and as effective as clopidogrel and aspirin in pre-
venting thrombotic complication after coronary stenting.
1063-57 Baseline Platelet Count Correlates With Ischemic 
Events and Mortality at Follow-Up After Percutaneous 
Coronary Intervention
Paul C. Lee, Annapoorna S. Kini, Prabha Rao, Thomas Joseph, Javed Suleman, 
Mazullah Kamran, Warren Sherman, Samin K. Sharma, Mount Sinai School of Medicine, 
New York, NY
Background: Role of baseline platelet count and outcome after PCI has not been well
established. It is possible that higher baseline platelet count may be associated with
increased ischemic complications.
Methods: We analyzed 4,232 consecutive patients who had PCI between July 1999 and
July 2002 from the database for peri-procedural events and survival at 365-days. Throm-
bocytopenic patients (platelet <150,000) were excluded from the study.
The remaining patients were divided into two groups: Normal platelet count group
(n=3,735) and high platelet count group (platelet count > 320,000, 90th percentile,
n=497).
Results: There were no differences in procedural, clinical success, minor complications,
or CKMB release between the two groups. The maximum ACT modestly correlated with
the platelet count (r=-0.1, p<0.0001).The incidence of stent thrombosis was higher in
patients with high platelet count compared to normal platelet count(0.6% vs.0.1%;
p<0.02). But, there was no difference noted in target vessel revascularization on follow-
up. The platelet count correlates with risk of stent thrombosis (c-statistic=0.68;p=0.0014).
Patients with high platelet count have a higher 365-day mortality (normal platelet: 1.3%;
high platelet: 3.2%; Hazard Ratio 2.5 [1.3,4.5], p=0.0002). This difference persisted
regardless of whether glycoprotein IIb/IIIa was used (p=0.0074). Proportional hazard
model adjusting for age, hemoglobin, clinical syndrome, creatinine, liver disease, diabe-
tes, use of Glycoprotein IIb/IIIa inhibitors and age shows that high platelet count strongly
predicts higher 365-day mortality (hazard ratio 3.2 [1.2, 4.7], p=0.03).
Conclusion: Baseline elevated platelet count is an independent predictor of long term
survival after PCI, perhaps partly related to increased risk of stent thrombosis and short
term MACE. Therefore, lifelong use of oral dual antiplatelet therapy may be indicated in
this high risk subgroup post PCI.
